Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blind, Position-controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of Quadrivalent Influenza Virus Split Vaccine in 6-35 Months of Age

NCT05642078 is registered in ClinicalTrials.gov with Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. as lead sponsor.

NCT NCT05642078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05642078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blind, Position-controlled Phase III Clinical Trial to Evaluate the Immunogenicity and Safety of Quadrivalent Influenza Virus Split Vaccine in 6-35 Months of Age
Lead sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
February 18, 2023
Completion date
January 5, 2024
Enrollment
2,550 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prevention of influenza